CSIMarket
 
Syros Pharmaceuticals Inc   (SYRS)
 

The Deficit has expanded even more at the Syros Pharmaceuticals Inc in the third quarter of 2022

SYRS recorded third quarter of 2022 operating loss of $-39.454 million


Published 2022-11-16T22:24:25+00:00
Goran Soko / CSIMarket.com Contributer


Dryvax_pdWeak business caused growth in losses for the third quarter of 2022 financial report, Syros Pharmaceuticals Inc s' net deficit per share grew to $-3.21 from $-0.41 where Revenue fell by -31.701 % to $3.89 million from $5.70 million a year before.

In contrast to the Q2 Revenue Tumbled by -38.002 % from $6.28 million and increased deficit from $-0.54 per share.


For the third quarter of 2022 Syros Pharmaceuticals Inc realized net deficit of $-30.253 million, higher than $-26.027 million a year ago.


Syros Pharmaceuticals Inc is expected to report next financial earnings on August 08, 2023.



Syros Pharmaceuticals Inc's ROA

Syros Pharmaceuticals Inc's Net Income Growth



Other SYRS's Earnings Reports








Other SYRS's Earnings Reports








Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071